Clinical Trial

Qishenyiqi Dripping Pill for Coronary Microvascular Disease

Study acronym: CMVD
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.
Trial Details
NCT Number NCT06699420
Lead Sponsor Qilu Hospital of Shandong University
Conditions Coronary Microvascular Disease
Enrollment 162 participants
Start Date 2023-11-08
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-21